1 / 37

To screen or not to screen

To screen or not to screen. ANTENATAL SCREENING. Jim Gray Consultant Microbiologist Birmingham Women’s Hospital James.gray@bwnft.nhs.uk. Overview. Current infection screening arrangements National Screening Committee Programme Other How screening might change

siusan
Download Presentation

To screen or not to screen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. To screen or not to screen ANTENATAL SCREENING Jim Gray Consultant Microbiologist Birmingham Women’s Hospital James.gray@bwnft.nhs.uk

  2. Overview • Current infection screening arrangements • National Screening Committee Programme • Other • How screening might change • Future research opportunities

  3. To Screen or Not to ScreenAntenatal screening • Stakeholders • National Screening Committee • Department of Health • Public Health England • NICE • RCOG

  4. NHS Infectious Diseases in Pregnancy Screening Programme • Uptake >97% • 1,749/688,755 (0.25%) HIV-positive • 3,982/690,760 (0.58%) hepatitis B positive • 944/678,611 (0.14%) syphilis-positive • 44,650/677,479 (6.59%) rubella non-immune

  5. Infection screening in pregnancy • NSC Infectious Diseases in Pregnancy Screening Programme • HIV • Hepatitis B • Syphilis • Rubella immunity • NSC endorsed screening • Asymptomatic bacteriuria • Other screening • Chlamydia • GBS • AMR bacteria

  6. NHS Infectious Diseases in Pregnancy Screening Programme (2013) • Uptake >97% • 1,749/688,755 (0.25%) HIV-positive • 3,982/690,760 (0.58%) hepatitis B positive • 944/678,611 (0.14%) syphilis-positive • 44,650/677,479 (6.59%) rubella non-immune

  7. HIV screening • AIM • To prevent paediatric HIV infection • OBJECTIVES • To identify all HIV positive women • To ensure the rapid referral of all HIV positive women for assessment and management within a multi-disciplinary team

  8. Hepatitis B screening • AIM • To prevent perinatal hepatitis B infection • OBJECTIVES • To ensure all hepB +vewomen are identified • To ensure all hepb +ve women are referred for specialist assessment and management within 6 weeks • To ensure infants are appropriately vaccinated; 1st dose within 24 h & schedule completed

  9. Syphilis screening • AIM • To prevent congenital syphilis infection • OBJECTIVES • To identify all women with positive syphilis screening test results early in pregnancy • To ensure their rapid assessment by an appropriate specialist, e.g. GUM within a multi-disciplinary environment

  10. Rubella screening • AIM • To reduce the risk of congenital rubella in future pregnancies • OBJECTIVES • To ensure all women susceptible to rubella infection (<10 IU/ml) are identified • To ensure these women are offered postnatal MMR • To ensure that the 1st dose is administered prior to discharge from maternity services, & the GP is contacted regarding the 2nd dose

  11. How accurate is rubella immunity screening? UK NEQAS distribution 3148

  12. How accurate is rubella immunity screening? UK NEQAS distribution 3148

  13. How accurate is rubella immunity screening? UK NEQAS distribution 3148

  14. Rubella screening • Screening for rubella susceptibility does not meet the UK NSC criteria for a screening programme. • The IDPS programme is currently working collaboratively with the PHE Immunisation team and plan to cease antenatal screening for rubella susceptibility. The present arrangements for antenatal screening and post-partum immunisation will continue until other arrangements are in place.

  15. Screening for asymptomatic bacteriuria • External review of screening for ASB in pregnancy for the UKNSC July 2011 • Policy should continue but justification changed from prevention of preterm delivery to prevention of pyelonephritis • Not clear whether the test should use culture

  16. NICE CG62: Antenatal care for uncomplicated pregnancies Women should be offered routine screening for asymptomatic bacteriuria by midstream urine culture early in pregnancy. Identification and treatment of asymptomatic bacteriuria reduces the risk of pyelonephritis.

  17. Asymptomatic bacteriuria in pregnancy • Symptomatic UTI in pregnancy is frequently preceded by asymptomatic bacteriuria • Prevalence is around 5% • Untreated, at least 30% of women with ASB will develop acute pyelonephritis • Screening for ASB is considered to be a cost effective approach to preventing pyelonephritis

  18. A screening programme may prevent 6480 cases of pyelonephritis per year

  19. Asymptomatic bacteriuria in pregnancy Many research questions • What is the clinical & cost effectivness of screening? • How should screening be undertaken? • When should screening be undertaken? • How should women with ASB be monitored during their pregnancy?

  20. Until it is clear that antenatal screening for GBS carriage does more good than harm and that the benefits are cost-effective, the National Screening Committee does not recommend routine screening in the UK. Is this statement not also true of the antenatal ASB screening?

  21. ASB screening – where does this leave us? • Culture is said to be more accurate than dip testing, but we don’t know whether dip testing is accurate in identifying women at risk of PN • We don’t know what the impact of ASB screening is on antibiotic use antenatally • Too much? (because we treat people who don’t need treatment) • Too little? (because without coordinated arrangements to oversee patient management there is no assurance that all women with ASB receive treatment )

  22. Other NICE recommendations • Chlamydia trachomatis • At the booking appointment, healthcare professionals should inform pregnant women younger than 25 years about the high prevalence of chlamydia infection in their age group, and give details of their local National Chlamydia Screening Programme. • Chlamydia screening should not be offered as part of routine antenatal care.

  23. More NICE recommendations • Do not screen for: • Bacterial vaginosis • CMV • Hepatitis C • Toxoplasmosis • Group B Streptococci (GBS)

  24. The Prevention of Early-onset Neonatal Group B Streptococcal DiseaseRCOG Green–top Guideline No. 36 Until it is clear that antenatal screening for GBS carriage does more good than harm and that the benefits are cost-effective, the National Screening Committee does not recommend routine screening in the UK.

  25. The Prevention of Early-onset Neonatal Group B Streptococcal DiseaseRCOG Green–top Guideline No. 36 • IAP offered to: • Women with a previous baby with neonatal GBS disease • Women with GBS in current pregnancy • Women who are pyrexial in labour should be offered broad-spectrum antibiotics including an antibiotic for prevention of neonatal EOGBS disease

  26. The Prevention of Early-onset Neonatal Group B Streptococcal DiseaseRCOG Green–top Guideline No. 36 • Role of IAP unclear for: • Women with preterm labour (<37 weeks’ gestation) and prelabourrupture of membranes of any duration • Women with preterm labour & prolonged rupture of membranes (>18 h)

  27. What would be the aim of GBS screening? • To prevent neonatal GBS disease by administering intrapartum antibiotic prophylxis (IAP) to mothers during labour • To assist in ruling out infection in newborn babies with soft signs of infection

  28. What would be the aim of GBS screening?

  29. ALL PREGNANT WOMEN: RISK FACTORS FOR GBS NO 80% of women NO ANTIBIOTICS GIVEN YES 20% of women INTRAPARTUM ANTIBIOTICS GIVEN A small number of these women will deliver a GBS-infected baby Only around 30% of these women will have GBS; 70% (14% of all labouring women) will receive IAP that is of no value

  30. Cepheid GeneXpert GBS • Moderately complex testing with < 1 min hands-on time • Results turnaround time 55 minutes • Manufacturer claims 99.0% sensitivity and 92.4% specificity

  31. GBS1 Universal PCR screening not cost effective ALL PREGNANT WOMEN: RISK FACTORS FOR GBS NO 80% of women NO ANTIBIOTICS GIVEN YES 20% of women INTRAPARTUM ANTIBIOTICS GIVEN GBS2 A small number of these women will deliver a GBS-infected baby Only around 30% of these women will have GBS; 70% (14% of all labouring women) will receive IAP that is of no value

  32. Implementation of modified admission MRSA screening guidance for NHS (2014) • Trusts should: • Identify and screen patients in high MRSA risk specialties, e.g. adult/paediatricICUs, NICUs, HDUs • Identify and re-screen any patient previously known to be MRSA positive

  33. Public Health England: Acute trust toolkit for the early detection, management and control of carbapenemase-producing Enterobacteriaceae (CPE) • Suspected case: a patient who, in the last 12 m, has been an inpatient in a hospital abroad or a UK hospital which has problems with spread of CPE or is a previously +ve case • Management: take rectal swab & isolate patient (with en-suite). Apply strict standard precautions until three conseutive negative rectal swabs collected 48 h apart

  34. Conclusions • The UKNSC Infection Screening Programme is highly effective • However, there is a lot of additional antenatal infection screening that is not performed in a systematic and coordinated way • If this screening is clinically- and cost-effective why could it not be incorporated into the highly effective management arrangements that already exist for the UKNSC Programme?

More Related